Off-label use of approved drugs: therapeutic opportunity and challenges.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004348:Drug Labeling; D004363:Drug Utilization / Q000941:ethics / Q000592:standards*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D000069285:Infliximab; D014481:United States; D014486:United States Food and Drug Administration; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D000069285:Infliximab